Skip to main content
The Globe and Mail
Support Quality Journalism.
The Globe and Mail
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
Just$1.99
per week
for first 24 weeks

Enjoy unlimited digital access
Cancel Anytime
Enjoy Unlimited Digital Access
Canada’s most-awarded
newsroom for a reason
Stay informed for a
lot less, cancel anytime
“Exemplary reporting on
COVID-19” – Herman L
$1.99
per week
for 24 weeks
Get full access to globeandmail.com
Just $1.99per week for the first 24weeks
Just $1.99per week for the first 24weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(select.open)}function setPanelState(o){dom.root.classList[o?"add":"remove"](select.open),dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); } //

A health-care worker receives a Johnson & Johnson vaccine at a hospital in Cape Town, South Africa, on Feb. 17, 2021.

Nardus Engelbrecht/The Associated Press

Some Africans are hesitating to get COVID-19 vaccines amid concerns about their safety, alarming public health officials as some countries start to destroy thousands of doses that expired before use.

Malawi and South Sudan in recent days have said they will destroy some of their doses, a concerning development on a continent where health officials have been outspoken about the need for vaccine equity as the world’s rich nations hold the bulk of shots.

Africa, whose 1.3 billion people represent 16 per cent of the world’s population, has received less than 2 per cent of the COVID-19 vaccine doses administered around the world, according to the World Health 0rganization.

Story continues below advertisement

The continent has confirmed more than 4.5 million COVID-19 cases, including 120,000 deaths, a tiny fraction of the global fatalities and caseload. But some experts worry that the 54-nation continent will suffer in the long term if it takes longer than expected to meet the threshold scientists believe is needed to stop uncontrolled spread of COVID-19 – 70 per cent or higher of the population having immunity through vaccination or past infection.

Africa seeks to vaccinate up to 60 per cent of its people by the end of 2022.

Achieving that goal will require about 1.5 billion vaccine doses for Africa if the two-shot AstraZeneca vaccine continues to be widely used. But safety concerns relating to that vaccine, often the main shot available under the donor-backed COVAX program to ensure access for developing countries, have left some Africans worried.

Vaccine-related suspicions have been spread widely on social media, driven partly by a general lack of trust in authorities. Uganda’s health minister had to refute allegations she faked receiving a shot, even posting a video of herself getting the jab on Twitter, along with the admonition: “Please stop spreading fake news!”

Some have raised the untrue claim that the shots can cause infertility on sites such as WhatsApp. Others openly question the speed with which COVID-19 vaccines have been developed.

“The world has failed to find a vaccine for AIDS all these years, but they quickly found a vaccine for COVID? I am not going to go for that vaccine,” said Richard Bbale, an electrician in the Ugandan capital, Kampala, voicing fear that an experimental vaccine could be harmful. “Even if the government forces us to get the vaccine as if it’s a national ID, I will not go.”

Austin Demby, Sierra Leone’s health minister, told reporters last week that a third of the 96,000 doses the country received in March will likely not be used before they expire, citing a lack of urgency among some people who decided that COVID-19 is “not as bad as Ebola,” which ravaged the country several years ago.

Story continues below advertisement

“People are worried this is another public experiment they want to make on our people,” he said.

The World Health Organization and the Africa Centers for Disease Control and Prevention have urged African governments to continue rolling out the AstraZeneca vaccine, saying its benefits outweigh any risks after European countries limited its use over concerns about rare blood clots in a small number of recipients.

“Anything you take has a risk. Any medication,” Africa CDC director John Nkengasong told a briefing last week, citing some essential drugs that can cause blood clots in rare cases. “That’s the way we should be looking at these vaccines.”

The Africa CDC said in a statement last week it had received guidance from the Serum Institute of India recommending a three-month “shelf life extension” on the April 13 expiration date of at least a million AstraZeneca shots delivered to Africa.

Africa nations “don’t have a choice,” Nkengasong said, urging Malawi to use all its shots after authorities in the southern African nation said they would burn 16,000 AstraZeneca doses that expired earlier in April.

It is unclear if Malawi will follow that advice.

Story continues below advertisement

The country has administered less than half of more than 500,000 doses it received via COVAX, leading Victor Mithi, head of the Society of Medical Doctors in Malawi, to blame vaccine misconceptions.

“We are continuously assuring Malawians that the vaccine is safe and that once they feel anything abnormal beyond the usual post-vaccination symptoms, they can always come to the hospital and report,” he said.

An additional 1.26 million doses expected from COVAX at the end of May may be wasted if people continue shunning the vaccine, said Shouts Simeza, president of the National Organization of Nurses and Midwives in Malawi, adding that a possible solution is making vaccinations mandatory for all who are eligible.

Trying to increase coverage, Malawi’s government has relaxed vaccine eligibility rules to include everyone aged 18 and older after initially focusing on priority groups such as health workers.

The East African nation of Uganda, which also is struggling to increase vaccine rollout among priority groups, may soon act similarly, said Emmanuel Ainebyoona, spokesman for the Ministry of Health. Ugandans under age 50 have shown interest in getting vaccinated, raising hope that doses will not expire unused, he said.

Uganda has received 964,000 doses of the AstraZeneca vaccine, the only one available in the country. But just over 230,000 doses have been administered since March 10.

Story continues below advertisement

Health authorities had planned to give at least 500,000 people their first shot in a first round of vaccinations targeting front-line workers, people with underlying health conditions and those 50 and older.

But, amid a slow rollout, they are now reaching out to popular “influencers,” celebrities such as a kickboxer who was photographed getting a shot last week.

“The uptake is gradually improving,” Ainebyoona said, noting that “communications interventions” have proved necessary to get more Ugandans to embrace the vaccination campaign.

A few thousand people are inoculated daily at centres put up across the country, including inside regional hospitals. The local Daily Monitor newspaper recently reported that more than 280,000 doses will likely expire by July at the current average of about 6,000 shots used each day.

Vaccination teams, lacking official records of eligible residents, simply sit and wait for people who may not show up.

Intricate, automated mini-factories are essential to get COVID-19 vaccines into syringes and vials so they can find their way into people’s arms. A family owned company in Italy can’t keep up with demand for their machines that can wash, sterilize and fill vials by the hundreds per minute. The Globe and Mail

Sign up for the Coronavirus Update newsletter to read the day’s essential coronavirus news, features and explainers written by Globe reporters and editors.

Your Globe

Build your personal news feed

  1. Follow topics and authors relevant to your reading interests.
  2. Check your Following feed daily, and never miss an article. Access your Following feed from your account menu at the top right corner of every page.

Follow topics related to this article:

View more suggestions in Following Read more about following topics and authors
Report an error
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

If you do not see your comment posted immediately, it is being reviewed by the moderation team and may appear shortly, generally within an hour.

We aim to have all comments reviewed in a timely manner.

Comments that violate our community guidelines will not be posted.

UPDATED: Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies